Free Trial
NASDAQ:CDT

CDT Equity 5/14/2024 Earnings Report

CDT Equity logo
$0.75 +0.03 (+4.38%)
Closing price 09/22/2025 04:00 PM Eastern
Extended Trading
$0.74 -0.02 (-2.35%)
As of 05:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CDT Equity EPS Results

Actual EPS
-$75.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CDT Equity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CDT Equity Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

CDT Equity's next earnings date is estimated for Thursday, November 13, 2025, based on past reporting schedules.

Conference Call Resources

CDT Equity Earnings Headlines

CDT Executes Cryptocurrency Treasury Reserve Strategy
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
CDT Board Authorizes Adoption of Cryptocurrency Treasury Reserve Strategy
See More CDT Equity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

View CDT Equity Profile

More Earnings Resources from MarketBeat